Efficacy and Safety of Adjunctive Aripiprazole in Schizophrenia: Meta-Analysis of Randomized Controlled Trials

Journal of Clinical Psychopharmacology

Volumn 36, Issue 6, 2016, Pages 628-636

  Zheng, Wei ^a   Zheng, Ying Jun ^a   Li, Xian Bin ^b,c   Tang, Yi Lang ^b,d   Wang, Chuan Yue ^b,c   Xiang, Ying Qiang ^b   De Leon, Jose ^e,f,g  

^a GUANGZHOU MEDICAL UNIVERSITY   (China)

^b CAPITAL MEDICAL UNIVERSITY   (China)

^c CAPITAL MEDICAL UNIVERSITY   (China)

^d EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e Eastern State Hospital   (United States)

^f UNIVERSITY OF GRANADA   (Spain)

^g UNIVERSITY OF THE BASQUE COUNTRY UPV EHU   (Spain)

Author keywords

aripiprazole; clozapine; metabolic; negative symptoms; schizophrenia; weight gain

Indexed keywords

ARIPIPRAZOLE; NEUROLEPTIC AGENT; PLACEBO; PROLACTIN;

ADD ON THERAPY; ANXIETY DISORDER; ARTICLE; BODY MASS; BODY WEIGHT; BODY WEIGHT DISORDER; BRIEF PSYCHIATRIC RATING SCALE; COMPARATIVE EFFECTIVENESS; CONSTIPATION; DROWSINESS; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; ECG ABNORMALITY; EXTRAPYRAMIDAL SYMPTOM; HUMAN; HYPERSALIVATION; INTERVENTION STUDY; MENTAL DISEASE; MENTAL PATIENT; META ANALYSIS; METABOLISM; NEGATIVE SYNDROME; POSITIVE AND NEGATIVE SYNDROME SCALE; POSITIVE SYNDROME; PRIORITY JOURNAL; PSYCHOPHARMACOTHERAPY; RANDOMIZED CONTROLLED TRIAL (TOPIC); SCHIZOPHRENIA; SEX DIFFERENCE; SYSTEMATIC REVIEW; TACHYCARDIA; TREATMENT OUTCOME; DRUG POTENTIATION; STATISTICS AND NUMERICAL DATA;

ANTIPSYCHOTIC AGENTS; ARIPIPRAZOLE; DRUG SYNERGISM; HUMANS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SCHIZOPHRENIA;

EID: 84991436090     PISSN: 02710749     EISSN: 1533712X     Source Type: Journal    
DOI: 10.1097/JCP.0000000000000579     Document Type: Article

References (82)

1. Mago R. Proposed strategies for successful clinical management with aripiprazole. Expert Opin Pharmacother. 2008;9:1279-1290.
2. Charpeaud T, Samalin L, Llorca PM. Efficacy of aripiprazole for the treatment of schizophrenia: what dose is required? Encéphale. 2014;40: 62-73.
3. Khanna P, Suo T, Komossa K, et al. Aripiprazole versus other atypical antipsychotics for schizophrenia. Cochrane Database Syst Rev. 2014; 1:CD006569.
4. Stark AD, Jordan S, Allers KA, et al. Interaction of the novel antipsychotic aripiprazole with 5-HT1A and 5-HT 2A receptors: functional receptor-binding and in vivo electrophysiological studies. Psychopharmacology (Berl). 2007;190:373-382.
5. Sommer IE, Begemann MJ, Temmerman A, et al. Pharmacological augmentation strategies for schizophrenia patients with insufficient response to clozapine: a quantitative literature review. Schizophr Bull. 2012;38:1003-1011.
6. Mizuno Y, Suzuki T, Nakagawa A, et al. Pharmacological strategies to counteract antipsychotic-induced weight gain and metabolic adverse effects in schizophrenia: a systematic review and meta-analysis. Schizophr Bull. 2014;40:1385-1403.
7. Srisurapanont M, Suttajit S, Maneeton N, et al. Efficacy and safety of aripiprazole augmentation of clozapine in schizophrenia: a systematic review and meta-analys 8. Furlan AD, Pennick V, Bombardier C, et al. 2009 Updated Method Guidelines for Systematic Reviews in the Cochrane Back Review Group. Spine (Phila Pa 1976). 2009;34:1929-1941.
8. Moher D, Liberati A, Tetzlaff J, et al. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. Ann Intern Med. 2009;151:264-269, W264.
9. Chang JS, Ahn YM, Park HJ, et al. Aripiprazole augmentation in clozapine-treated patients with refractory schizophrenia: an 8-week, randomized, double-blind, placebo-controlled trial. J Clin Psychiatry. 2008; 69:720-731.
10. Chi L, Shen XW, Mu QJ. Study of aripiprazole and little dose of clozapine in the treatment of refractory schizophrenia. Chin J Pract Nerv Dis. 2012; 15:7-9(Chinese).
11. Deng YX. The efficacy and safety of aripiprazole combined with low dose clozapine in treatment of refractory schizophrenia. Contemp Med Forum. 2014;12:254-255(Chinese).
12. Ding ZS, Li D. A study of aripiprazole combined with clozapine in refractory schizophrenia. Med J Chin People Health. 2010;22:1780-1781(Chinese).
13. Fan X, Borba CP, Copeland P, et al. Metabolic effects of adjunctive aripiprazole in clozapine-treated patients with schizophrenia. Acta Psychiatr Scand. 2013;127:217-226.
14. Fleischhacker WW, Heikkinen ME, Olie JP, et al. Effects of adjunctive treatment with aripiprazole on body weight and clinical efficacy in schizophrenia patients treated with clozapine: a randomized, double-blind, placebo-controlled trial. Int J Neuropsychopharmacol. 2010;13: 1115-1125.
15. Guan Y. The efficacy and safety of aripiprazole combined with clozapine in treatment of refractory schizophrenia. J BengbuMed Coll. 2014;39: 1084-1086(Chinese).
16. Li X. The clinical efficiency of aripiprazole with clozapine for the female refractory schizophrenia. Chin J Gen Pract. 2013;11:1573-1577(Chinese).
17. Liang Y, Liu MD. Effects of aripiprazole combined with low doses of clozapine on the negative symptoms and cognitive function of schizophrenia patients. Int Med Chin. 2013;8:118-119(Chinese).
18. Luo HX, Song XQ, Li Y, et al. The efficacy of aripiprazole combined with low dose clozapine in treatment of schizophrenia. Chin J Trauma Disabil Med. 2014;22:128-129 (Chinese).
19. Ma Q, Lian HT, Li LX. A study of aripiprazole combined with clozapine in refractory schizophrenia. Med J Chin People Health. 2007;19:1046-1048(Chinese).
20. Muscatello MR, Bruno A, Pandolfo G, et al. Effect of aripiprazole augmentation of clozapine in schizophrenia: a double-blind, placebo-controlled study. Schizophr Res. 2011;127:93-99.
21. Ren L, Sun JS. A control study of aripiprazole combined with clozapine in schizophrenia. Mod J Integr Trad Chin West Med. 2008;17:1160-1161(Chinese).
22. Sun H. A control study of clozapine plus aripiprazole in the treatment of male treatment-resistant schizophrenia. J Clin Psychosom Dis. 2010;16: 510-512(Chinese).
23. Sun WH, Chen Y, Wang KY. The study of combining clozapine and aripiprazole for the treatment of negative symptoms of schizophrenia. Med J Chin People Health. 2012;24:2592-2594(Chinese).
24. Wang XL, Hou CL, Lan RL, et al. A study of low dose clozapine combined with aripiprazole in the treatment of schizophrenia. J Psychiatr. 2011;24: 129-130(Chinese).
25. Wang FJ, Zhou ZP. The clinical research of aripiprazole combined with clozapine in chronic schizophrenia. Med J Chin People Health. 2012;24: 2833-2835 (Chinese).
26. Xu QH, Xu JQ, Chen ZX, et al. The clinical efficacy of aripiprazole combined with low dose clozapine in treatment of schizophrenia. J Guangdong Med Coll. 2014;32:85-87(Chinese).
27. Xu YY. The effect of small dose of clozapine combined aripiprazole on weight and glucolipid metabolism for psychopaths. Chin J Clin Rational Drug Use. 2013;6:126-127(Chinese).
28. Yin Y, Xie XL, Huang XQ. The clinical efficiency of aripiprazole combined with clozapine in treatment of refractory schizophrenia. Jiangxi Med J. 2014;49:360-362(Chinese).
29. Zhang XM, Shao CY, Wang QJ, et al. A clinical study of aripiprazole combined with clozapine in refractory schizophrenia. Med Inform. 2011; 24:2784(Chinese).
30. Chen JH, Wu YF, Liao XZ. The treatment efficacy of olanzapine combined with aripiprazole in female first-episode schizophrenia. Guide Chin Med. 2012;10:145-146(Chinese).
31. Chen L. The efficacy and safety of aripiprazole combined with risperidone in treatment of schizophrenia. For All Health. 2014;8:141-142(Chinese).
32. Chen JX, Zhang RZ, Li W, et al. Adjunctive treatment of risperidone-induced hyperprolactinemia with aripiprazole: a randomized, double-blind, placebo-controlled study. Chin J New Drug. 2014;23: 811-814(Chinese).
33. Henderson DC, Fan X, Copeland PM, et al. Aripiprazole added to overweight and obese olanzapine-treated schizophrenia patients. J Clin Psychopharmacol. 2009;29:165-169.
34. Jin JF, Cao YQ, Xu LP, et al. The study of low doses of aripiprazole on preventing the hyperprolactinemia induced by chlorpromazine. J Psychiatr. 2008;21:455-456(Chinese).
35. Kane JM, Correll CU, Goff DC, et al. A multicenter, randomized, double-blind, placebo-controlled, 16-week study of adjunctive aripiprazole for schizophrenia or schizoaffective disorder inadequately treated with quetiapine or risperidone monotherapy. J Clin Psychiatry. 2009;70: 1348-1357.
36. Lai DL, Hu WP, Feng CP. The efficacy of aripiprazole combined with olanzapine in the treatment of first-episode schizophrenia. Modern Diagnos Treat. 2014;25:4646-4647 (Chinese).
37. Lee BJ, Lee SJ, Kim MK, et al. Effect of aripiprazole on cognitive function and hyperprolactinemia in patients with schizophrenia treated with risperidone. Clin Psychopharmacol Neurosci. 2013;11:60-66.
38. Li YJ, Gao H. Effect of aripiprazole combined with risperidone for lowering serum prolactin in schizophrenic patients. China Pharmaceuticals. 2014;23:88-90(Chinese).
39. Li H, Ren KW. A controlled study of aripiprazole combined with sulpiride in treatment of schizophrenia. Chin J Misdiagnostics. 2011;11:823-824(Chinese).
40. Li B, Wang LN, Zhou GQ, et al. Control study on olanzapine alone and combination with aripiprazole in the treatment of schizophrenia. J Clin Psychiatry. 2012;22:411-412(Chinese).
41. Li WJ, Liu XH. A control study of aripiprazole combined with low-dose clozapine in the treatment of schizophrenia. J Clin Psychiatry. 2013;23:72(Chinese).
42. Liang J, Yan J, Zhang XY. Aripiprazole reduces paliperidone-induced increase of prolactin in patients with schizophrenia: a randomized, double blind and placebo-controlled study. Chinese. J New Drugs. 2014;23: 1300-1303 1310 (Chinese).
43. Liu C. A comparative study of aripiprazole combined with risperidone in the treatment of schizophrenia. World Health Digest. 2013;37:125(Chinese).
44. Ou YH, Shi JA, Chen FB. The effect of aripiprazole on serum levels of insulin-like growth factor -1 in schizophrenia treated with olanzapine. Chin J Health Psychol. 2014;22:161-163(Chinese).
45. Pan JY, Wei YL. Clinical observation of aripiprazole orally disintegrating tablets on weight gain and prolactin increase caused by risperidone and sulpiride. Youjiang Med J. 2014;42:48-50 53 (Chinese).
46. Pan Q, Yang SJ, Han X, et al. Efficacy of aripiprazole on insulin resistance in schizophrenia patientswith olanzapine treatment. Chin JHealth Psychol. 2014;22:986-988(Chinese).
47. Ren LZ, Hu M. A study of aripiprazole in treatment of hyperprolactinemia induced by sulpiride. Med Inform. 2011;24:2455(Chinese).
48. Shim JC, Shin JG, Kelly DL, et al. Adjunctive treatment with a dopamine partial agonist, aripiprazole, for antipsychotic-induced hyperprolactinemia: a placebo-controlled trial. Am J Psychiatry. 2007;164:1404-1410.
49. Shu G. A case-control study of risperidone and risperidone combined with low doses of aripiprazole in treatment of schizophrenia. Med J Chin People Health. 2012;24:2085-2086(Chinese).
50. Sun W, Zhang JL, Kang MX. Effects of adjunctive aripiprazole on body weight and hyperprolactinemia induced by olanzapine in schizophrenia. Sichuan Mental Health. 2011;24:98-100(Chinese).
51. Sun XG. Effects of adjunctive low dose aripiprazole in treatment of hyperprolactinemia induced by risperidone. Med J Chin People Health. 2012;24:1343-1344(Chinese).
52. Wang LL, Xun ZY. A control study on female schizophrenia treated with risperidone combined with low dose aripiprazole. Taijin Pharma. 2010;22:40-42(Chinese).
53. Wang XL, Xie J. Effects of aripiprazole combined with amisulpride in treatment of schizophrenia with negative symptoms. J Qiqihar Univ Med. 2013;34:1734-1735(Chinese).
54. Xiong Y. The efficacy and safety of antipsychotic combination in treatment of first-onset schizophrenia. Contemp Med Forum. 2014;12:180-181(Chinese).
55. Xu HX, Shi L, Yang YL, et al. Effects of quetiapine only and combined with aripiprazole on the body mass of patients with schizophrenia. J Clin Psychiatry. 2013;23:127-128(Chinese).
56. Xue L, Zhou LJ, Tan WZ, et al. Effects of adjunctive aripiprazole in treatment of hyperprolactinemia induced by risperidone. Jilin Med J. 2012; 33:107-108(Chinese).
57. Yang SZ. The study on aripiprazole and risperidone in treatment of first-onset schizophrenia. Hebei Med. 2013;19:1348-1351(Chinese).
58. Yang YX, Chen BH, Xu XJ, et al. A controlled study on aripiprazole combined with risperidone in the treatment of chronic schizophrenia. Chin J Clin Pharmacol. 2013;29:419-422(Chinese).
59. Yasui-Furukori N, Kaneda A, Sugawara N, et al. Effect of adjunctive treatment with aripiprazole to atypical antipsychotics on cognitive function in schizophrenia patients. J Psychopharmacol. 2012;26:806-812.
60. Zhao YQ. A control study on aripiprazole reduces risperidone-induced weight gain and increase of prolactin in patients with schizophrenia. Sichuan Mental Health. 2013;26:122-123(Chinese).
61. Zhou HS, Li B, Liu J, et al. The effect of aripiprazole on schizophrenic patients' increased body mass caused by risperidone. Chin J Health Psychol. 2012;20:810-811(Chinese).
62. Zhou P, Liu LQ, Hao JF, et al. The study of aripiprazole on preventing the hyperprolactinemia induced by antipsychotics on female schizophrenic patients. J Int Psychiatry. 2014;41:69-72(Chinese).
63. Zhuo ZL, Wang QY, Xiong Y, et al. Clinical observation of aripiprazole orally disintegrating tablets in the improvement of women's weight, prolactin increase caused by risperidone, sulpiride, olanzapine. Chinese Community Doctors. 2015;31:5-6(Chinese).
64. DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials. 1986;7:177-188.
65. Egger M, Davey Smith G, Schneider M, et al. Bias in meta-analysis detected by a simple, graphical test. BMJ. 1997;315:629-634.
66. Moher D, Pham B, Jones A, et al. Does quality of reports of randomised trials affect estimates of intervention efficacy reported in meta-analyses? Lancet. 1998;352:609-613.
67. Atkins D, Best D, Briss PA, et al. Grading quality of evidence and strength of recommendations. BMJ. 2004;328:1490.
68. Balshem H, Helfand M, Schunemann HJ, et al. GRADE guidelines, 3, Rating the quality of evidence. J Clin Epidemiol. 2011;64:401-406.
69. DeQuardo JR. Increased efficacy with addition of clozapine to aripiprazole: alternative explanations. J Clin Psychiatry. 2005;66:396.
70. Karunakaran K, Tungaraza TE, Harborne GC. Is clozapine-aripiprazole combination a useful regime in the management of treatment-resistant schizophrenia? J Psychopharmacol. 2007;21:453-456.
71. Clarke LA, Lindenmayer JP, Kaushik S. Clozapine augmentation with aripiprazole for negative symptoms. J Clin Psychiatry. 2006;67:675-676.
72. Henderson DC, Kunkel L, Nguyen DD, et al. An exploratory open-label trial of aripiprazole as an adjuvant to clozapine therapy in chronic schizophrenia. Acta Psychiatr Scand. 2006;113:142-147.
73. Mitsonis CI, Dimopoulos NP, Mitropoulos PA, et al. Aripiprazole augmentation in the management of residual symptoms in clozapine-treated outpatients with chronic schizophrenia: an open-label pilot study. Prog Neuropsychopharmacol Biol Psychiatry. 2007;31:373-377.
74. Wang LJ, Ree SC, Huang YS, et al. Adjunctive effects of aripiprazole on metabolic profiles: comparison of patients treated with olanzapine to patients treated with other atypical antipsychotic drugs. Prog Neuropsychopharmacol Biol Psychiatry. 2013;40:260-266.
75. Song TJ, Leng HF, Zhong LL, et al. CONSORTin China: past development and future direction. Trials. 2015;16:243.
76. Li XB, Tang YL, Wang CY, et al. Clozapine for treatment-resistant bipolar disorder: a systematic review. Bipolar Disord. 2015;17:235-247.
77. Bo QJ, Wang ZM, Li XB, et al. Adjunctive metformin for antipsychotic-induced hyperprolactinemia: A systematic review. Psychiatry Res. 2016;237:257-263.
78. Li XB, Tang YL, Zheng W, et al. QT interval prolongation associated with intramuscular ziprasidone in Chinese patients: a case report and a comprehensive literature review with meta-analysis. Case Rep Psychiatry. 2014;2014:489493.
79. ZhengW, Li XB, Tang YL, et al. Metformin for weight gain and metabolic abnormalities associated with antipsychotic treatment: meta-analysis of randomized placebo-controlled trials. J Clin Psychopharmacol. 2015;35:499-509.
80. Kennedy-Martin T, Curtis S, Faries D, et al. A literature review on the representativeness of randomized controlled trial samples and implications for the external validity of trial results. Trials. 2015;16:495.
81. Rabinowitz J, Levine SZ, Barkai O, et al. Dropout rates in randomized clinical trials of antipsychotics: a meta-analysis comparing first- and second-generation drugs and an examination of the role of trial design features. Schizophr Bull. 2009;35:775-788.
82. Kriston L. Dealing with clinical heterogeneity in meta-analysis. Assumptions, methods, interpretation. Int J Methods Psychiatr Res. 2013;22:1-15.